Targacept, AstraZeneca Face Another Failure With NNR Class
This article was originally published in The Pink Sheet Daily
Executive Summary
The Targacept/AstraZeneca partnership faces another major setback as they decide not to file their neuronal nicotinic receptor modulator TC-5214 in major depressive disorder. Targacept CEO chalks the trial failure up to the gray areas of depression trial design.